Schizophrenia News

CHICAGO — Patients with tardive dyskinesia reported greater impact on quality of life than health care providers, according to a poster at the International Association of Parkinsonism and Related Disorders World Congress.

Click Therapeutics announced it has enrolled the first patient in a clinical trial of an investigational prescription digital therapeutic to support standard antipsychotic treatment of schizophrenia, according to a company press release.

A biopharmaceutical company announced it has dosed the first patient in a clinical trial of a long-acting oral treatment for schizophrenia, schizoaffective disorder and bipolar I disorder, according to a company press release.

Patients with schizophrenia experienced earlier onset and higher rates of hip fractures compared with the general population, according to study results published in JAMA Network Open.

Young adults with any mental disorder are at 58% greater risk for MI and 42% greater risk for stroke compared with those without a mental illness, data from a population-based study show.

The FDA approved a long-acting formulation for the treatment of schizophrenia, according to a press release from the manufacturers.

The FDA has approved a new drug application for aripiprazole, an extended-release injection for the treatment of schizophrenia and bipolar disorder, according to a press release from the manufacturers.

Young people with schizophrenia had elevated risk for sudden cardiac death, and biopsychosocial factors related to social isolation impacted the cardiac risk factor burden in individuals with schizophrenia, researchers reported.

KarXT was efficacious and safe in and well-tolerated by people with schizophrenia, according to a press release from its manufacturer.

People with treatment-resistant schizophrenia experienced improvement with evenamide added to antipsychotics compared with antipsychotics alone, according to results from a 6-week trial.